MYi Diagnostics is a biomedical company that has expertise in multiplexed proteomic profiling for precision medicine. MYI Diagnostics performs research in order to substitute many targeted diagnostics for individual cancers, infectious diseases, metabolic conditions, and other rare disorders or conditions.
MYi Diagnostics develops a single-cell quantification technology that is intended to treat cancer. The company develops multiplexed immunocytochemical analytical platforms for assaying patient biopsies to identify the unique biomarkers that identify diseased cells, enabling healthcare providers to generate actionable information to streamline clinical intervention strategies.
The company is leveraging DNA technologies for high-throughput quantification of multitude of proteins in a single sample, with sensitivity down to a single cell.
MYi developed a technology to analyze multiple molecules in a drop of blood using a modular platform. The company aims to facilitate academic research and reduce costs of routine blood tests in the clinic.